CorMedix (CRMD) closed the last trading session at $5.52, gaining 33.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $13 indicates a 135.5% upside potential.The mean estimate comprises four short-term price targets with a standard deviation of $4.55. While the lowest estimate of $9 indicates a 63% increase from the current price level, the most optimistic analyst expects the sto ...